Digestive System Diseases

633 trials 301 recruiting

Filter these 633 trials by phase, country and sponsor.

Open in Search →

(IPCOM) Influence of Proton pump inhibitor CO-medication on the absorption of innovator and generic formulations of Mycophenolate mofetil Ended

2024-517043-32-00 Post Transplantation Patients 6 2025-07-08
Evaluation of the bioequivalence of two products containing esomeprazole under fasting conditions: Esomeprazole-Syrup 40 mg dose (Test) vs. … Ended

2024-512401-89-00 No therapeutic indication in the current trial with hea 2 2025-06-12
A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic … Ended

2023-507771-22-01 Primary Biliary Cholangitis (PBC) 5 2025-04-03
Evaluation of the bioequivalence of two products containing esomeprazole under fed conditions: Esomeprazole-Syrup 40 mg dose (Test) vs. Nexi… Ended

2024-512674-97-00 No therapeutic indication in the current trial with hea 2 2025-03-11
A pilot, open label, single dose, randomized, four-period, four-sequence, four-treatment crossover, comparative bioavailability study of UDC… Ended

2024-519920-26-00 UDCA causes a reduction in cholesterol saturation of th 2 2025-02-20
A Mass Balance Study of [14C]-IPN60250 in Healthy Adult Participants Ended

2024-515195-12-00 Primary sclerosing cholangitis (PSC) 3 2025-02-18
Testing Insulin Enemas for Ulcerative Colitis: A First-Stage Clinical Trial Ended

2023-510335-11-00 Ulcerative colitis 3 2025-02-04
Study to compare drug availability in bloodstream of two oral formulations of mesalazine in healthy volunteers under fed conditions. Ended

2024-517107-37-00 Chronic idiopathic inflammatory bowel disease 3 2024-12-20
A study to compare two different aramchol formulations in healthy volunteers. Ended

2023-507445-28-00 Nonalcoholic fatty liver disease 3 2024-12-18
Study to evaluate food effect on the pharmacokinetics of mesalazine oral formulation in healthy volunteers. Ended

2024-514748-10-00 Ulcerative colitis 3 2024-11-28
An open-label, multicentric, phase I study with expansion cohorts, evaluating the safety and the efficacy of combination of atezolizumab, ti… Ended

2024-516717-20-00 Metastatic non small cell lung cancer (Phase I and expa 3 2024-11-27
Optical PD-L1 imaging using Quantitative Fluorescence Endoscopy in locally advanced esophageal cancer using durvalumab-680LT: a phase I mult… Ended

2024-517258-85-00 Esophageal cancer 1 2024-11-21
Evaluation of bioequivalence of two products containing 50 mg dimenhydrinate: Dimenhydrinate 50 mg (Test) vs. Vomex A 50 mg Lösung zum Einne… Ended

2024-515170-27-00 No therapeutic indication in the current trial with hea 2 2024-11-15
PARADOX study Ended

2024-515278-28-00 ulcerative colitis 6 2024-11-15
Investigating the safety, feasibility, and optimal dose of risankizumab-800CW in IBD - NAVIGATE study Ended

2024-515358-25-00 Inflammatory Bowel Disease (IBD) 7 2024-11-08
Double-blind placebo-controlled cross-over MRI study to evaluate the effect of naloxegol and codeine on gastrointestinal motility and volume… Ended

2024-512673-28-00 Opioid-induced constipation 6 2024-10-28
An open label, randomized, single dose, two-sequence, two-treatment, four-period, fully replicate, cross-over pharmacokinetic study comparin… Ended

2024-516942-21-00 Not applicable (submitted trial is a bioavailability st 2 2024-10-21
A Clinical Trial to Assess the Safety of SOR102 in Healthy Participants and Patients with Ulcerative Colitis Ended

2023-510324-77-00 Ulcerative colitis 1 2024-10-20
Dasatinib and quercetin, a combination of senolytics to treat fibrotic non-alcoholic fatty liver disease; The TRUTH study Ended

2024-517593-21-00 MASLD 4 2024-10-14
A TWO-PART ABSOLUTE BIOAVAILABILITY STUDY DESIGNED TO EVALUATE THE PHARMACOKINETIC PROFILE OF VELUSETRAG FOLLOWING SINGLE-DOSE ADMINISTRATIO… Ended

2024-513988-70-00 chronic intestinal pseudo-obstruction (CIPO) 3 2024-10-07
A Phase 1b, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of MB… Ended

2023-507376-50-00 Ulcerative Colitis 1 2024-09-27
Dose-finding and safety study of a new Shigella vaccine combined with an adjuvant in the Netherlands and Zambia Ended

2023-506394-35-02 Vaccination against shigellosis (in healthy adults) 3 2024-09-12
A Phase I study to evaluate the pharmacokinetics, safety and tolerability of multiple oral doses of obefazimod in participants with renal im… Ended

2024-514561-20-00 Moderately to severely active ulcerative colitis 3 2024-09-09
A Study to Learn How Different Amounts and Forms of the Study Intervention Called PF-07899895 are Tolerated and Act in the Body of Healthy A… Ended

2023-507354-32-00 Ulcerative Colitis 1 2024-09-09